CELLINK Acquires Nanoscribe, Visikol - IDEX Health & ScienceIDEX Health & Science

    Disclaimer:

    The views, information, or opinions expressed in the Industry News RSS feed belong solely to the author and do not necessarily represent those of IDEX Health & Science and its employees.

    CELLINK Acquires Nanoscribe, Visikol

    Article obtained from Photonics RSS Feed.

    The CELLINK Group, a bioconvergence company focused on the application areas of bioprinting, multiomics, cell line development, and diagnostics, strengthened its position in the biophotonics space with a pair of acquisitions totaling up to $78 million. The company acquired Nanoscribe, a spinout from the Karlsruhe Institute of Technology that is developing two-photon polymerization tools, and Visikol, a contract research services company that offers 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology services to pharma and biotech companies.

    CELLINK will acquire all outstanding shares of Nanoscribe in a two-phase cash and stock agreement. The initial purchase price will be £34 million ($48.01 million)…

    READ MORE
    May, 26 2021 |

    IDEX Health & Science is the global authority in fluidics and optics, bringing to life advanced optofluidic technologies with our products, people, and engineering expertise. Intelligent solutions for life.